Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

AstraZeneca Files for Market Approval of Tremelimumab in China for Hepatocellular Carcinoma

Fineline Cube Oct 18, 2024

The Center for Drug Evaluation (CDE) has indicated on its website that AstraZeneca (NASDAQ: AZN),...

Company Medical Device

MicroPort CardioFlow’s Heart Valve Balloon Dilatation Catheter Alwide Plus Gains Mexican Approval

Fineline Cube Oct 18, 2024

MicroPort Scientific Corp., a leading Chinese medical device company (HKG: 0853), through its spin-off MicroPort...

Company Drug

Changshan Biochemical Pharmaceutical Wins Marketing Approval for Enoxaparin in Niger

Fineline Cube Oct 18, 2024

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced...

Company Drug

Huahai Pharmaceutical Gets FDA Nod for Generic Empagliflozin and Metformin ANDA

Fineline Cube Oct 18, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a prominent Chinese pharmaceutical company, has announced the...

Company Drug

Laekna Advances Obesity Treatment Candidate LAE102 with Subcutaneous Dosing in Phase I Study

Fineline Cube Oct 18, 2024

Laekna, a Sino-US biotech firm, has announced the commencement of a subcutaneous dosing cohort within...

Company Deals

Sanofi Invests EUR 300 Million in Joint Venture with Orano Med for Next-Generation Radioligand Therapies

Fineline Cube Oct 18, 2024

Sanofi (EPA: SAN), a leading French pharmaceutical company, has entered into a strategic agreement with...

Company Drug

Antengene’s Xpovio Secures Expanded Access in South Korea for Multiple Myeloma Treatment

Fineline Cube Oct 18, 2024

Antengene Corp., Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that it has received...

Company Drug

AbbVie’s Vyalev Wins FDA Approval as First Subcutaneous Levodopa Therapy for Advanced Parkinson’s

Fineline Cube Oct 18, 2024

AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the US, has received approval from...

Policy / Regulatory

Chengdu Drafts Comprehensive Policy to Stimulate Biomedical Industry Growth

Fineline Cube Oct 18, 2024

The Chengdu Municipal Bureau of Economic and Information Technology has unveiled a draft proposal titled...

Company Drug

Chongqing Zhifei Biological’s EC Injection Receives Market Approval in Indonesia

Fineline Cube Oct 18, 2024

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a leading biopharmaceutical company based in China, has...

Company Deals

Tencent Invests USD 30 Million in Early Cancer Detection Firm Insighta, Backed by Prenetics

Fineline Cube Oct 18, 2024

Prenetics Global Limited (NASDAQ: PRE), a prominent health sciences company with operations in the US...

Company Deals

LaNova Medicines Secures RMB 300 Million in Series C1 Financing to Advance Cancer Therapy Pipeline

Fineline Cube Oct 18, 2024

LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the successful completion of...

Company

Abbott Laboratories Posts 9.4% Q3 Sales Growth, Driven by Medical Devices and Pharmaceuticals

Fineline Cube Oct 18, 2024

Abbott Laboratories (NYSE: ABT), a U.S.-based healthcare giant, has reported its financial results for the...

Company Deals

Chengdu Baiyu Pharmaceutical Strikes Licensing Deal with Novartis for Unannounced Anti-Tumor Asset

Fineline Cube Oct 18, 2024

Chengdu Baiyu Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, has entered into a licensing agreement...

Company Deals

Cryofocus Medtech Partners with Guangzhou Medical University Hospital for Cryoballoon Ablation R&D

Fineline Cube Oct 17, 2024

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the...

Company Drug

Kintor Pharmaceutical Initiates Phase II/III Trial for KX-826 Tincture 1.0% in Treating Male Androgenetic Alopecia

Fineline Cube Oct 17, 2024

Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the commencement...

Company Medical Device

Novocure’s Optune Lua Wins FDA Approval for mNSCLC Treatment in Combination with Immunotherapies

Fineline Cube Oct 17, 2024

Novocure (NASDAQ: NVCR), a Swiss firm renowned for its pioneering Tumor Treating Fields (TTFields) cancer...

Company Deals

Servier and HUST Forge Partnership to Cultivate Innovative Therapies through SHINEDocs Program

Fineline Cube Oct 17, 2024

French pharmaceutical company Servier has joined forces with Huazhong University of Science and Technology (HUST),...

Company Drug

Innovent Biologics’ Picankibart Achieves Positive Results in Phase II UC Study

Fineline Cube Oct 17, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company

Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration

Fineline Cube Oct 17, 2024

Bayer AG (ETR: BAYN), a German multinational pharmaceutical and life sciences giant, has announced the...

Posts pagination

1 … 309 310 311 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.